![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Author: Hägg Staffan Jönsson Anna K Spigset Olav
Publisher: Informa Healthcare
ISSN: 1474-0338
Source: Expert Opinion on Drug Safety, Vol.8, Iss.5, 2009-09, pp. : 537-547
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Assessment of the Risk for Venous Thromboembolism Among Users of Hormone Replacement Therapy
By Oger E.
Drugs & Aging, Vol. 14, Iss. 1, 1999-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Antipsychotic-Induced Venous Thromboembolism: A Review of the Evidence
By Hägg S.
CNS Drugs, Vol. 16, Iss. 11, 2002-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Bevacizumab: increased risk of venous thromboembolism
Reactions Weekly, Vol. 1, Iss. 1230, 2008-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Bevacizumab: increased risk of venous thromboembolism
Inpharma, Vol. 1, Iss. 1666, 2008-01 ,pp. :